Understanding Your Pathology Report: Breast Cancer - cytokeratin in breast cancer


Cytokeratins in the detection of tumors cytokeratin in breast cancer

May 05, 2005 · Recent publications have classified breast cancers on the basis of expression of cytokeratin-5 and -17 at the RNA and protein levels, and demonstrated the importance of these markers in defining sporadic tumours with bad prognosis and an association with BRCA1-related breast cancers. These important observations using different technology platforms produce a new functional Cited by: 315.

Cytokeratin immunohistochemistry (IHC) reveals a higher rate of occult lymph node metastases among lobular carcinomas than among ductal breast cancers. IHC is widely used but is seldom recommended for the evaluation of sentinel lymph nodes in breast cancer patients. 189 patients (42%) had some type Cited by: 107.

women with a previous history of breast cancer. There are no markers specific for breast cancer although prominent staining for estrogen receptor (ER) α can be very supportive (1). A combination of markers such as low molecular weight cytokeratins, cytokeratin 7, cytokeratin 20, epithelial membrane antigen, thyroid transcription factor.

CK5 is a marker of breast luminal progenitor and stem cells (Breast Cancer Res Treat 2011;128:45) CK5 positive cells may represent a chemoresistant population in breast and ovarian cancer (Breast Cancer Res Treat 2011;128:45, Int J Gynecol Cancer 2015;25:1565).

Apr 16, 2013 · Breast cancer is recognised to be a heterogeneous disease and the second most common cause of morbidity and mortality worldwide in women. Basal-like breast cancer (BLBC) is associated with aggressive characteristics including development of recurrent disease Cited by: 21.